CELYAD SA/ADR (CYAD) to Post FY2023 Earnings of ($0.91) Per Share, SunTrust Banks Forecasts

Share on StockTwits

CELYAD SA/ADR (NASDAQ:CYAD) – Equities research analysts at SunTrust Banks issued their FY2023 EPS estimates for shares of CELYAD SA/ADR in a note issued to investors on Monday, March 18th. SunTrust Banks analyst P. Lawson forecasts that the company will post earnings of ($0.91) per share for the year.

Several other research firms also recently commented on CYAD. William Blair reissued a “buy” rating on shares of CELYAD SA/ADR in a research note on Tuesday, December 4th. Zacks Investment Research downgraded shares of CELYAD SA/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Finally, HC Wainwright lifted their price target on shares of CELYAD SA/ADR from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. CELYAD SA/ADR presently has an average rating of “Buy” and an average target price of $45.40.

CYAD stock opened at $21.87 on Wednesday. The company has a market cap of $222.52 million, a price-to-earnings ratio of -6.18 and a beta of 1.83. CELYAD SA/ADR has a one year low of $15.36 and a one year high of $37.20.

Several hedge funds have recently bought and sold shares of the business. Millennium Management LLC raised its stake in shares of CELYAD SA/ADR by 69.6% during the fourth quarter. Millennium Management LLC now owns 90,597 shares of the company’s stock worth $1,645,000 after acquiring an additional 37,171 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of CELYAD SA/ADR by 4.1% during the fourth quarter. Victory Capital Management Inc. now owns 646,351 shares of the company’s stock worth $11,738,000 after acquiring an additional 25,189 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of CELYAD SA/ADR by 1,109.0% during the third quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after acquiring an additional 5,545 shares in the last quarter. 7.62% of the stock is currently owned by hedge funds and other institutional investors.

About CELYAD SA/ADR

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Featured Article: Bull Market

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

-$0.33 Earnings Per Share Expected for Achieve Life Sciences Inc  This Quarter
-$0.33 Earnings Per Share Expected for Achieve Life Sciences Inc This Quarter
Docusign Inc  Expected to Announce Quarterly Sales of $220.11 Million
Docusign Inc Expected to Announce Quarterly Sales of $220.11 Million
Veoneer Inc  Given Average Rating of “Hold” by Analysts
Veoneer Inc Given Average Rating of “Hold” by Analysts
Research Analysts’ Upgrades for June, 25th
Research Analysts’ Upgrades for June, 25th
Analysts Set $1.00 Target Price for TOP SHIPS Inc
Analysts Set $1.00 Target Price for TOP SHIPS Inc
BP Midstream Partners LP  Receives Average Recommendation of “Hold” from Brokerages
BP Midstream Partners LP Receives Average Recommendation of “Hold” from Brokerages


 
© 2006-2019 Zolmax.